Intravenous immunoglobulin (IVIg) can exert beneficial effects in autoimmune and inflammatory diseases via several mutually non-exclusive mechanisms. While, IVIg can directly modulate the functions of both innate and adaptive immune cells such as dendritic cells (DC), macrophages, B and T cells, several reports have also highlighted that the regulation of immune responses by IVIg can be indirect. In view of these results, we aimed at exploring whether indirect regulation of immune cells by 'IVIg-educated' innate cells is a universal phenomenon. We addressed this question by deciphering the modulation of B cell functions by 'IVIg-educated' DC. Our results indicate that human B cells are resistant to immunomodulation by 'IVIg-educated' DC. However, IVIg at therapeutic concentrations can directly inhibit B cell activation and proliferation. These results thus suggest that, indirect modulation of immune cells by IVIg is not a universal phenomenon. © 2011 Elsevier B.V..

Jagadeesh Bayry

Biological Sciences and Engineering

M.S. Maddur

P. Hegde

M. Sharma

S.V. Kaveri

Indian Institute of Technology Palakkad&nbsp;(IIT Palakkad or IIT PKD) is a public autonomous&nbsp;engineering&nbsp;and&nbsp;research&nbsp;institute located in&nbsp;Palakkad,&nbsp;Kerala. It was&nbsp;one of the five new&nbsp;IITs&nbsp;proposed in the&nbsp;2014 Union budget of India. The campus was inaugurated on 3 August 2015. The institute has 94 faculty, 978 students, and 63 non-teaching staffs.

IT Palakkad currently offers four-year Bachelor of Technology (B.Tech) and two years MS programmes in 8 different engineering disciplines including&nbsp;Computer Science, Electrical, Mechanical, Civil among others.

&nbsp;

IIT Palakkad

Autoimmunity Reviews

Increased incidence of fungal infections in the immunocompromised individuals and fungi-mediated allergy and inflammatory conditions in immunocompetent individuals is a cause of concern. Consequently, there is a need for efficient therapeutic alternatives to treat fungal infections and inflammation. Several studies have demonstrated that antibodies or immunoglobulins have a role in restricting the fungal burden and their clearance. However, based on the data from monoclonal antibodies, it is now evident that the efficacy of antibodies in fungal infections is dependent on epitope specificity, abundance of protective antibodies, and their isotype. Antibodies confer protection against fungal infections by multiple mechanisms that include direct neutralization of fungi and their antigens, inhibition of growth of fungi, modification of gene expression, signaling and lipid metabolism, causing iron starvation, inhibition of polysaccharide release, and biofilm formation. Antibodies promote opsonization of fungi and their phagocytosis, complement activation, and antibody-dependent cell toxicity. Passive administration of specific protective monoclonal antibodies could also prove to be beneficial in drug resistance cases, to reduce the dosage and associated toxic symptoms of anti-fungal drugs. The longer half-life of the antibodies and flexibilities to modify their structure/forms are additional advantages. The clinical data obtained with two monoclonal antibodies should incite interests in translating pre-clinical success into the clinics. The anti-inflammatory and immunoregulatory role of antibodies in fungal inflammation could be exploited by intravenous immunoglobulin or IVIg. © 2014, Springer-Verlag Berlin Heidelberg.

Fulltext

Seminars in Immunopathology

The protective role of immunoglobulins in fungal infections and inflammation

B cells are resistant to immunomodulation by 'IVIg-educated' dendritic cells

Journal	Autoimmunity Reviews
Publisher	ELSEVIER
ISSN	15689972
Open Access	No